Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | WRN | Q14191 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22127640 | 1.00 | NAAA (0.48) | NAAACYP19A1GAAMAPTADRA2A | |
| SCHEMBL28154352 | 0.84 | NAAA (0.50) | NAAACYP19A1GAAADRA2AADRA1A | |
| SCHEMBL22028559 | 0.84 | ADRA2A (0.54) | CYP19A1MAPTADRA2AADRA1ABLM | |
| SCHEMBL126952 | 0.84 | NAAA (0.50) | NAAACYP19A1GAAHTTCHRNB2 | |
| SCHEMBL24586928 | 0.84 | NAAA (0.50) | NAAACYP19A1GAAADRA2AADRA1A | |
| SCHEMBL23926234 | 0.84 | MGAM (0.44) | CYP19A1GAAMAPTADRA2AADRA1A | |
| SCHEMBL21518280 | 0.84 | NAAA (0.50) | NAAACYP19A1GAAHTTBLM | |
| SCHEMBL28572438 | 0.84 | NAAA (0.50) | NAAACYP19A1GAAHTTCHRNB2 | |
| SCHEMBL20581506 | 0.83 | MAPT (0.47) | NAAACYP19A1MAPTADRA2AADRA1A | |
| SCHEMBL23159167 | 0.83 | MAPT (0.47) | NAAACYP19A1MAPTADRA2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20210177877-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| EP-3801496-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | Flagship Pioneering Innovations V, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3801587-A1 | ACYLATED CATECHIN POLYPHENOLS AND METHODS OF THEIR USE FOR THE TREATMENT OF CANCER | Flagship Pioneering Innovations V, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20210085640-A1 | ACYLATED CATECHIN POLYPHENOLS AND METHODS OF THEIR USE FOR THE TREATMENT OF CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-03-25 | — | — | US | disclosed |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING, INC. | 2020-06-25 | — | — | US | disclosed |
| US-10391750-B2 | Cover window plate and image display device including the same | DONGWOO FINE-CHEM CO., LTD. (KR) | 2019-08-27 | — | — | US | disclosed |
| US-20180178494-A1 | COVER WINDOW PLATE AND IMAGE DISPLAY DEVICE INCLUDING THE SAME | DONGWOO FINE-CHEM CO., LTD. (KR) | 2018-06-28 | — | — | US | disclosed |
| US-20120270142-A1 | PHOTOSENSITIVE COMPOSITION AND METHOD OF MANUFACTURING A SUBSTRATE FOR A DISPLAY DEVICE USING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-10-25 | — | — | US | disclosed |
| US-20120064455-A1 | PHOTORESIST COMPOSITION AND METHOD OF FORMING PATTERN USING THE SAME | SAMSUNG TECHWIN CO., LTD. (KR) | 2012-03-15 | — | — | US | disclosed |
| CN-1818778-A | Photosensitive resin composition, thin film panel and method for manufacturing thin film panel | SAMSUNG ELECTRONICS CO LTD (KR) | 2006-08-16 | — | — | CN | disclosed |
| US-20060177767-A1 | Photosensitive resin composition, thin film panel including a layer made from photosensitive resin composition, and method for manufacturing thin film panel | SAMSUNG ELECTRONICS CO., LTD. | 2006-08-10 | — | — | US | disclosed |
| CN-1266544-C | Photosnesitive resin composition comprising quinonediazide sulfate ester compound | DONGJIN SEMICHEM CO LTD (KR) | 2006-07-26 | — | — | CN | disclosed |
| CN-1568444-A | Photosnesitive resin composition comprising quinonediazide sulfate ester compound | DONGJIN SEMICHEM CO LTD (KR) | 2005-01-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FABP1, PYGL, LIPC | NAAA 883/4885CYP19A1 993/4885GAA 62/4885 |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | NAAA 883/4885CYP19A1 993/4885GAA 62/4885 |
| US-20210085640-A1 | ACYLATED CATECHIN POLYPHENOLS AND METHODS OF THEIR USE FOR THE TREATMENT OF CANCER | ACAT2, ACAT1, FABP6 | NAAA 321/4885CYP19A1 456/4885GAA 317/4885 |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | NAAA 883/4885CYP19A1 993/4885GAA 62/4885 |
| US-20210177877-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | NAAA 883/4885CYP19A1 993/4885GAA 62/4885 |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FABP1, PYGL, LIPC | NAAA 883/4885CYP19A1 993/4885GAA 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.